We are live on ! Find out more
AMAM

Ambrx Biopharma Inc
AMAM

Delisted

AMAM was delisted on the 6th of March, 2024.

Back to rankings

20 hedge funds and large institutions have $266M invested in Ambrx Biopharma Inc in 2021 Q2 according to their latest regulatory filings, with 20 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
20
Holders Change
+20
Holders Change %
–
% of All Funds
0.35%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
20
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$64.2M
2
CAM
Cormorant Asset Management
Massachusetts
+$42.4M
3
FI
Fosun International
China
+$32.9M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$31.1M
5
SCM
Suvretta Capital Management
New York
+$19.9M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$68.7M +$64.2M +3,766,940 New
CAM
2
Cormorant Asset Management
Massachusetts
$47M +$42.4M +2,486,386 New
FI
3
Fosun International
China
$37.9M +$32.9M +1,932,591 New
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$35.8M +$31.1M +1,827,292 New
SCM
5
Suvretta Capital Management
New York
$22.9M +$19.9M +1,169,529 New
BlackRock
6
BlackRock
New York
$16.7M +$14.5M +850,676 New
AG
7
Artal Group
Luxembourg
$16.7M +$14.5M +850,000 New
OCA
8
Octagon Capital Advisors
New York
$8.82M +$7.67M +450,000 New
Millennium Management
9
Millennium Management
New York
$2.82M +$2.46M +144,092 New
MIM
10
Monashee Investment Management
Massachusetts
$2.16M +$1.87M +110,000 New
AllianceBernstein
11
AllianceBernstein
Tennessee
$1.37M +$1.19M +70,000 New
Norges Bank
12
Norges Bank
Norway
$1.37M +$1.19M +70,000 New
Tudor Investment Corp
13
Tudor Investment Corp
Connecticut
$1.18M +$1.02M +60,000 New
CCM
14
CAAS Capital Management
New York
$784K +$682K +40,000 New
GCM
15
Ghisallo Capital Management
Massachusetts
$784K +$682K +40,000 New
MWNA
16
Marshall Wace North America
New York
$640K +$556K +32,648 New
PHP
17
Parkman Healthcare Partners
Connecticut
$294K +$256K +15,000 New
BFM
18
Boothbay Fund Management
New York
$263K +$229K +13,422 New
PCM
19
Pinz Capital Management
New York
$20K +$17K +1,000 New
Bank of America
20
Bank of America
North Carolina
$2K +$1.88K +110 New

AMAM Hedge Fund Activity: Q2 2021 in Review

20 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Ambrx Biopharma Inc (AMAM) for Q2 2021, worth a combined $266M.

Buyers outnumbered sellers: 20 funds opened new AMAM positions and 0 closed out — a net gain of 20 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $64.2M.

  • 20 institutional investors held Ambrx Biopharma Inc (AMAM) as of Q2 2021, up from 0 in Q1 2021.
  • Funds reported $266M of Ambrx Biopharma Inc stock for Q2 2021.
  • 20 funds opened new Ambrx Biopharma Inc positions in Q2 2021 and 0 closed out, a net change of +20 holders.
  • The largest Ambrx Biopharma Inc buyer in Q2 2021 was Fidelity Investments, an estimated $64.2M added.

Based on aggregated 13F filings for Q2 2021.